Anlotinib: Revision history

From Glioblastoma Treatments
Jump to navigationJump to search

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

13 June 2024

  • curprev 20:4520:45, 13 June 2024‎ Lazy talk contribs‎ 2,893 bytes −4‎ No edit summary
  • curprev 20:4420:44, 13 June 2024‎ Lazy talk contribs‎ 2,897 bytes +2,897‎ Created page with "{{TreatmentInfo |drug_name=Anlotinib |FDA_approval=Under investigation; not yet FDA-approved |used_for=Various cancers including Non-Small Cell Lung Cancer (NSCLC), Soft Tissue Sarcoma, and Renal Cell Carcinoma; being investigated for Glioblastoma Multiforme (GBM) |clinical_trial_phase=Phase 2 and 3 (for different cancers); early-stage trials for GBM |common_side_effects=Hypertension, fatigue, hand-foot syndrome, diarrhea, proteinuria, thyroid dysfunction |OS_without=Med..."
Retrieved from "http://glioblastomatreatments.wiki:80/index.php?title=Anlotinib"